Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Cost of Revenue for 6 consecutive years, with $403000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 16.47% to $403000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a 526.6% increase, with the full-year FY2024 number at $6.0 million, up 143.7% from a year prior.
  • Cost of Revenue was $403000.0 for Q3 2025 at Vivos Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.7 million in Q4 2024 to a low of -$1.9 million in Q4 2023.
  • A 5-year average of $1.3 million and a median of $1.4 million in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: soared 814.93% in 2021, then crashed 199.9% in 2023.
  • Vivos Therapeutics' Cost of Revenue stood at $2.6 million in 2021, then dropped by 25.47% to $1.9 million in 2022, then plummeted by 199.9% to -$1.9 million in 2023, then soared by 346.48% to $4.7 million in 2024, then plummeted by 91.41% to $403000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cost of Revenue are $403000.0 (Q3 2025), $2.9 million (Q2 2025), and $358000.0 (Q1 2025).